KMT2A and leukemia: Although Pam3CSK4 alone did not inhibit the leukemic progression of MLL‐AF9 cells, combined treatment of FF‐10501‐01 and Pam3CSK4 significantly prolonged the survival of leukemia mice than treatment with either FF‐10501‐01 or Pam3CSK4 alone (Fig 7E and F).